Bortezomib Leads to More Complete Remissions in Patients With High-Risk Follicular Lymphoma

Andrew M. Evens, DO, MSc, on the early results of ECOG-ACRIN E2408 trial, which found that adding bortezomib to standard bendamustine-rituximab treatment increases the number of complete remissions in patients with high-risk lymphoma.

SHARE